Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial

In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on cardiovascular events.
MDedge News

source https://www.medscape.com/viewarticle/983610?src=rss